歸巢關(guān)聯(lián)細(xì)胞黏附分子(HCAM)活性蛋白
Active Homing Associated Cell Adhesion Molecule (HCAM)
CDW44; CD44; CSPG8; ECMR-III; HCELL; IN; LHR; MC56; MDU2; MDU3; MIC4; MUTCH-I; Pgp1; Hematopoietic Cell E- And L-Selectin Ligand; Chondroitin Sulfate Proteoglycan 8
- 編號(hào)UAPA670Hu62
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)4.5
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 588 ¥ 1470 ¥ 2940 ¥ 8820 ¥ 22050
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
Homing Associated Cell Adhesion Molecule (HCAM), also known as CD44, is a ubiquitously expressed transmembrane glycoprotein mediating cell responses to the extracellular microenvironment. CD44 is the major surface hyaluronan (HA) receptor, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human CD44 and biotinylated hyaluronan (HA). Briefly, biotin-linked HA were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul were then transferred to CD44-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST 3 times and incubation with Streptavidin-HRP for 1 hour, then wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μl stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human CD44 and biotinylated HA was shown in Figure 1, the EC50?for this effect is 0.08 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
